Company / Capital Expenditures
CRESCENT BIOPHARMA, INC. Capital Expenditures History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$919.0K
FY2025
5-year range
$82.1K / $919.0K
FY2021-FY2025
Trend
+242.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Capital Expenditures changed +242% YoY in FY2025, a notable deviation from the 4-year average annual change of +88%.
Based on SEC 10-K filings.
$919,000 in FY2025 with a 10-year CAGR of +27.3%.
Improved from $212,603 to $919,000 over the past 9 years.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +27.3%
Key checks
Key Insights
- CRESCENT BIOPHARMA, INC.'s capital expenditures has grown for 3 consecutive years.
- In FY2025, capital expenditures increased 242.2% year-over-year.
- Lowest capital expenditures in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $919.0K | +242.2% |
| FY2017 | $268.6K | +26.3% |
| FY2016 | $212.6K | +159.0% |
| FY2015 | $82.1K | -74.0% |
| FY2014 | $316.2K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026